Previous 10 | Next 10 |
home / stock / acogf / acogf news
Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerati...
Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company committed to developing novel therapies with the potential ...
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced tod...
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced...
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,...
Alpha Cognition press release ( OTCQB:ACOGF ): Q2 GAAP EPS of -$0.05. Cash and cash equivalents as of June 30, 2022 were $6.0M. For further details see: Alpha Cognition GAAP EPS of -$0.05
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,...
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from a ...
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from it...
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...
News, Short Squeeze, Breakout and More Instantly...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Sportsman's Warehouse Holdings Inc. (SPWH) is expected to report $-0.3 for Q4 2024 IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2024-01-31 Klepierre (KLPEF) is expected to report for Q4 2023 Steakholder Foods Ltd. (STKH) is expected to report for Q4 2023 R...